Stock Information
Nuvation Bio Inc (NUVB)
Ticker Symbol: NUVB
Exchange: NYSE
Sector: Pharmaceuticals
Market Cap: $1,516.31 mil
Piotroski score: 4
PE Ratio: N/A
EPS (TTM): -0.5996
Revenue (TTM): $0.18 M
Dividend Yield: N/A%
ROE: -57.48%
Latest News
-
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Wed, May 6, 2026 8:03 AM
-
Nuvation Bio to Participate in Upcoming Investor Conferences
Tue, May 5, 2026 4:06 PM
-
RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target
Tue, May 5, 2026 11:36 AM
-
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Tue, May 5, 2026 9:38 AM
-
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target
Tue, May 5, 2026 6:26 AM
-
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Mon, May 4, 2026 9:33 PM
-
Transcript : Nuvation Bio Inc., Q1 2026 Earnings Call, May 04, 2026
Mon, May 4, 2026 9:20 PM
-
Nuvation Bio (NYSE:NUVB) Soars 22% After Earnings Beat Fueled by Strong Lung Cancer Drug Launch
Mon, May 4, 2026 9:01 PM
-
Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.
Mon, May 4, 2026 4:13 PM
-
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Mon, May 4, 2026 4:11 PM
Key Financials
Financial data not available
